TickerTalks
Browse all tickers →
TickerTalks›$ORKA
ORORKA

Oruka Therapeutics, Inc.

Hot onWhy it's trendingX chatter spiked vs its recent normPrice and volume picking up
$ORKA·$3.3B·Biotechnology·Healthcare
$92.70+11.6%YTD+205.8%1Y+503.5%
Mentions · last 7 days
2026-07-10: 32 posts2026-07-11: 11 posts2026-07-12: 23 posts2026-07-13: 72 posts2026-07-14: 50 posts2026-07-15: 116 posts2026-07-16: 97 posts404+45%
Price updated 3h ago·X counts updated 1d ago
ORORKA
$ORKAOruka Therapeutics, Inc.
$92.70+11.63%404 posts+45%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ORKA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-07-16

The move is getting stronger, with heavier trading behind it.

Oruka up 508% in a year — psoriasis/autoimmune biotech rallying on APGE/ABBV M&A read-through.

Oruka Therapeutics is a clinical-stage biotech developing long-acting biologics for autoimmune conditions — primarily plaque psoriasis and generalized pustular psoriasis. The stock is up 508% over the past year and is trading at 87th percentile of 52-week range on multiple fresh catalysts.

  • Revenue is zero — this is a pre-commercial biotech; the $3.25B market cap reflects the probability-weighted call on the ORKA-1 lead compound reaching first-in-class status.
  • H.C. Wainwright reiterated ORKA Buy with $120 PT after commenting on the APGE/ABBV M&A deal — the read-through is that AbbVie paying up for Apogee validates the psoriasis-biologics space and increases takeout probability for ORKA.
  • 52-week position 87th percentile with position vs 200-day MA +94% — the tape is at extreme above-trend levels; today's move to $88+ in after-hours per corpus is on no company-specific news but pure M&A read-through.
  • The community grouping ORKA with RVMD and LBRX as the top-3 post-APGE plays captures the specific M&A-adjacent framing that's driving the tape.
  • The 'looks too good to be true' bull framing captures the exact concern — 508% T12M gain in a pre-revenue biotech requires either continued clinical progress or an actual takeout to sustain.

August 10 Q2 earnings is procedural; the real catalysts are ongoing ORKA-1 clinical readouts and any M&A activity following the APGE precedent. A positive Phase 2 readout or actual takeout announcement is where +508% T12M continues; a Phase 2 durability concern or the APGE M&A wave failing to materialize elsewhere is where the multiple compresses. Real hot-momentum biotech with real M&A read-through catalysts — the setup is asymmetric event-heavy.

Agrees with X sentimentThe bullish X take on the $120 H.C. Wainwright PT, the APGE/ABBV M&A read-through, and the ORKA/RVMD/LBRX top-3 grouping is analytically fair. The 'looks too good to be true' framing captures the appropriate skepticism — but the AbbVie precedent is real and the takeout thesis is coherent.

What to watch: Aug 10 Q2 earnings plus ongoing ORKA-1 clinical readouts and any M&A activity — positive Phase 2 readout or actual takeout is where +508% T12M continues. A Phase 2 durability concern or failed M&A wave is where the multiple compresses.

On the calendar: 2026-08-10 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-06-29

Oruka Therapeutics is at $88.70+ in after-hours, up $16+ on no news - 'values the company at $5.2B now, nice rally from less than $11.' H.C. Wainwright reiterated ORKA Buy with $120 PT (commenting on the APGE/ABBV M&A deal). Posters frame ORKA as one of the top 3 after exiting APGE shares (alongside RVMD and LBRX). The APGE/ORKA/SYRE/RLAY rally is being described as 'looks too good to be true.' Tone is loud bullish on the M&A read-through and chart breakout.

Read the AI verdict + X sentiment for $ORKA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing long-acting monoclonal antibodies (ORKA-001/002) for psoriasis and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ORKA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ORKA

Partial — Clinical-stage biotech developing long-acting monoclonal antibodies (ORKA-001/002) for psoriasis and inflammatory diseases; the GLP-1 pipeline bifurcation and ADA oral formulation competition creates tailwinds for one product line, not the full operation.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-34.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-27.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 13, 2026$-0.48$-0.55+12.2%
Q4 2025Mar 12, 2026$-0.45$-0.61+26.2%
Q3 2025Nov 12, 2025$-0.55$-0.56+1.8%
Q2 2025Aug 11, 2025$-0.46$-0.48+4.2%
Next earningsMon, Aug 10·consensus EPS $-0.49

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.58$-23.7M
Q4 FY25$0———$-0.54$-22.7M
Q3 FY25$0———$-0.69$-21.7M
Q2 FY25$0———$-0.58$-23.2M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.11-$2.41 – -$1.920
FY27$0$0 – $0-$2.51-$2.98 – -$2.310
FY28$0$0 – $0-$3.28-$5.73 – -$1.840
FY29$0$0 – $0-$4.26-$4.26 – -$4.260
FY30$75.6M$75.6M – $75.6M-$4.76-$4.76 – -$4.763

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.83%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+15.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+84.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.405-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 15Joana GoncalvesChief Medical Officer7.0K sh$604KSellJul 13Arjun AgarwalPresident10.0K sh$846KSellJul 1Sandler Laura LeeCOO5.0K sh$472KSellJul 1Fairmount Funds Management LlcDirector3.6M sh$300.0MSellJun 22Arjun AgarwalPresident1.6K sh$128KSellJun 15Arjun AgarwalPresident395 sh$28KSellJun 15Joana GoncalvesChief Medical Officer7.9K sh$551KSellJun 15Sandler Laura LeeCOO600 sh$42KSellJun 15Paul T QuinlanGeneral Counsel733 sh$51KSellJun 15Klein Lawrence OttoCEO1.7K sh$120K
1–10 of 17
+ 10 other (9 exempts · 1 conversion) in window

See when $ORKA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 1SC 13D/A
AI summary

Fairmount Funds Management LLC filed an amended Schedule 13D for ORKA (CUSIP 687604108), disclosing shared voting and dispositive power over 14,553,895 shares with zero sole power. Amendment to a previously disclosed 5%+ passive position.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Delaware 000-22873 36-3855489 disclosed voting results from its annual or special meeting. f Matters to a Vote of Security Holders. On June 2, 2026, Oruka Therapeutics, Inc. (the “ Company ”) held its Annual Meeting of Stockholders (the “ Annual Meeting ”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-vote...

SC 13D/AActivist amendmentMay 4SC 13D/A
AI summary

Amendment No. 5 to Schedule 13D filed by Fairmount Funds Management LLC reporting beneficial ownership of ORUKA THERAPEUTICS, INC. representing a 9% stake (0 shares), with investment intent. This SC 13D/A filing dated 2026-05-04 updates the holder's position and disclosed intentions.

424B5Prospectus supplement (offering)Apr 29424B5
AI summary

ORKA filed a 424B5 prospectus supplement on 2026-04-29 of 9,660,000 Shares at $0.001 per share. This represents dilution happening now.

424B5Prospectus supplement (offering)Apr 27424B5
AI summary

ORKA filed a 424B5 prospectus supplement on 2026-04-27 at $0.001 per share. This represents dilution happening now.

424B5Prospectus supplement (offering)Apr 27424B5
AI summary

ORKA filed a 424B5 prospectus supplement on 2026-04-27 at $0.001 per share. This represents dilution happening now.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Delaware 000-22873 36-3855489 disclosed: FD Disclosure. On April 27, 2026, Oruka Therapeutics, Inc. (“Oruka” or the “Company”) issued a press release, and made publicly available a data presentation, announcing results from its Phase 2a EVERLAST-A clinical trial of ORKA-001, its potentially best-in-class anti-IL-23 antibody, in patients with moderate-to-severe psoriasis (“PsO”). Oruka will host a conference call and webcast today, Monday, April 27, 2026, at 8:00 a.m., Eastern Time, to discuss the data results. The information in Item 7.

S-3Shelf registrationApr 2S-3
+ 17 other (6 13Gs · 2 proxys · 1 routine 8-K · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Meanfool.com·20d agoOruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?fool.com·23d agoOruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·36d agoWall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Tradezacks.com·38d agoAn Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Millionfool.com·48d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · last 7 days

No standout posts about $ORKA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport